Phase 2 SBIR for GP88-targeted drug candidate for breast cancer

A&G Pharmaceutical announced that it has received a Phase 2 Small Business Innovation Research (SBIR) grant for the development of a neutralizing therapeutic antibody against a novel cancer-associated protein, GP88. In human clinical trials, the GP88 tissue test has demonstrated that an increased expression or presence of GP88 in tumor tissue of breast cancer patients is associated with an increased risk of recurrence as well as decreased overall survival. In ongoing prospective trials for the GP88 blood test, breast cancer patients have been found to have elevated levels of GP88.

GP88 is a glycoprotein that plays a role in the development of human cancers, including breast and lung cancer. Overexpression of GP88 has been shown to be associated with cancer cell growth, survival, metastasis, and chemoresistance. The SBIR grant will support the humanization of the neutralizing antibody and ongoing preclinical trials.

For more information call (410) 884-4100 or visit www.agpharma.com.